Lisi Group (FII) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
21 Sep, 2026Executive summary
Achieved record half-year EBIT above €100M for the first time, up 22.8% year-over-year, with operating margin at 11.3%, driven by productivity gains and a higher-value product mix across divisions.
Revenue reached €942.9M, up 5.7% year-over-year, with organic growth of 9.2% despite negative currency effects and scope changes.
Net income increased 62.1% to €62.4M (6.6% of revenue), with diluted EPS at €1.34 (+67.5%).
Positive operating free cash flow of €5.9M, reversing a negative trend from H1 2025, with cash flow from operations at €119.4M (12.7% of revenue).
Strategic initiatives included automation, digitalization, new product development, and geographic rationalization.
Financial highlights
EBITDA rose to €148.3M (margin 15.7%), up €15.2M from H1 2025.
EBIT reached €106.2M, up 22.8% year-over-year.
CAPEX totaled €48.0M (5.1% of revenue), focused on capacity expansion and innovation.
Net debt increased to €265.1M (23.2% of equity), with gearing and leverage ratios well within covenant limits.
Operating free cash flow: €5.9M (vs. -€14.3M in H1 2025); net financial debt: €265.1M (23.2% of equity).
Outlook and guidance
2026 targets confirmed: aiming for a fourth consecutive year of improved key financial indicators and positive free cash flow.
Aerospace market remains robust with strong order backlog through 2027; focus on capacity expansion and productivity.
Automotive division continues structural repositioning, cost discipline, and integration of new sites.
Latest events from Lisi Group
- Aerospace-led growth lifted nine-month revenue 8%, offsetting automotive weakness.FII
Q3 2026 TU - Record aerospace growth drove Q1 2026 revenue up 10.9%, offsetting automotive weakness.FII
Q1 2026 TU - Record revenue, profit surge, and reduced debt driven by aerospace growth and medical division sale.FII
H2 2025 - Strong 9.1% revenue growth driven by aerospace, with key portfolio shifts in medical and automotive.FII
Q3 2025 TU - Record sales and EBIT growth in H1 2025, led by aerospace, with strong outlook confirmed.FII
H1 2025 - Aerospace drives 8.6% sales growth, offsetting automotive decline and medical stabilization.FII
Q3 2024 TU - Record sales and improved margins in H1 2024, led by strong aerospace performance.FII
H1 2024 - Aerospace and medical growth drove Q1 sales up 8.3%, offsetting automotive decline.FII
Q1 2025 TU - Record revenue and profit growth driven by aeronautics; outlook remains positive for 2025.FII
H2 2024